The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity

Y. Mándi, G. Farkas, M. Koltai, I. Beladi, J. M. Mencia-Huerta, Braquet

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The influence of the platelet-activating factor (PAF) antagonist, BN 52021, on human natural killer (NK) cell cytotoxicity against K 562 target cells was determined. Cytotoxicity was measured by a short-term (4 hr) 51Cr-release assay. The cytotoxicity was significantly reduced in the presence of PAF antagonist at concentrations from 30 to 120 μM. This reduction of killing was not due to the impairment of binding of effector cells to target cells. Pretreatment of K 562 target cells with the PAF antagonist led to a greater inhibition of NK cell cytotoxicity compared with that observed when the effector cells were preincubated with BN 52021. Thus, the inhibition of cytotoxicity appears to be due to an effect of BN 52021 on target cells rather than on lymphocytes. Furthermore, the increase in NK activity induced by interferon was less pronounced when BN 52021 was added in the incubation medium. The natural cytotoxicity of platelet-depleted or large granular lymphocyte-enriched effector cell populations was inhibited by the PAF antagonist in a similar manner. The effect of BN 52021 appears to be related to its specific PAF antagonistic activity since a similar action on NK cells was noted with two other structurally unrelated PAF antagonists, BN 52111 and WEB 2086. In contrast, Ginkgolide J (BN 52024), which is structurally related to BN 52021 but lacks PAF antagonistic activity, was ineffective in inhibiting NK cell cytotoxicity. Finally, synthetic PAF induces a dose-dependent cytotoxic action on K 562 cells and this effect of the autacoid is inhibited by BN 52021. These observations provide indirect evidence that PAF could play a role in the mechanism(s) of NK cytotoxicity.

Original languageEnglish
Pages (from-to)370-374
Number of pages5
JournalImmunology
Volume67
Issue number3
Publication statusPublished - 1989

Fingerprint

ginkgolide B
Platelet Activating Factor
Natural Killer Cells
WEB 2086
Autacoids
Lymphocytes
Population Growth

ASJC Scopus subject areas

  • Immunology

Cite this

Mándi, Y., Farkas, G., Koltai, M., Beladi, I., Mencia-Huerta, J. M., & Braquet (1989). The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity. Immunology, 67(3), 370-374.

The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity. / Mándi, Y.; Farkas, G.; Koltai, M.; Beladi, I.; Mencia-Huerta, J. M.; Braquet.

In: Immunology, Vol. 67, No. 3, 1989, p. 370-374.

Research output: Contribution to journalArticle

Mándi, Y, Farkas, G, Koltai, M, Beladi, I, Mencia-Huerta, JM & Braquet 1989, 'The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity', Immunology, vol. 67, no. 3, pp. 370-374.
Mándi, Y. ; Farkas, G. ; Koltai, M. ; Beladi, I. ; Mencia-Huerta, J. M. ; Braquet. / The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity. In: Immunology. 1989 ; Vol. 67, No. 3. pp. 370-374.
@article{1f56cd4b68874f8f887c6ff6b1c7e3fb,
title = "The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity",
abstract = "The influence of the platelet-activating factor (PAF) antagonist, BN 52021, on human natural killer (NK) cell cytotoxicity against K 562 target cells was determined. Cytotoxicity was measured by a short-term (4 hr) 51Cr-release assay. The cytotoxicity was significantly reduced in the presence of PAF antagonist at concentrations from 30 to 120 μM. This reduction of killing was not due to the impairment of binding of effector cells to target cells. Pretreatment of K 562 target cells with the PAF antagonist led to a greater inhibition of NK cell cytotoxicity compared with that observed when the effector cells were preincubated with BN 52021. Thus, the inhibition of cytotoxicity appears to be due to an effect of BN 52021 on target cells rather than on lymphocytes. Furthermore, the increase in NK activity induced by interferon was less pronounced when BN 52021 was added in the incubation medium. The natural cytotoxicity of platelet-depleted or large granular lymphocyte-enriched effector cell populations was inhibited by the PAF antagonist in a similar manner. The effect of BN 52021 appears to be related to its specific PAF antagonistic activity since a similar action on NK cells was noted with two other structurally unrelated PAF antagonists, BN 52111 and WEB 2086. In contrast, Ginkgolide J (BN 52024), which is structurally related to BN 52021 but lacks PAF antagonistic activity, was ineffective in inhibiting NK cell cytotoxicity. Finally, synthetic PAF induces a dose-dependent cytotoxic action on K 562 cells and this effect of the autacoid is inhibited by BN 52021. These observations provide indirect evidence that PAF could play a role in the mechanism(s) of NK cytotoxicity.",
author = "Y. M{\'a}ndi and G. Farkas and M. Koltai and I. Beladi and Mencia-Huerta, {J. M.} and Braquet",
year = "1989",
language = "English",
volume = "67",
pages = "370--374",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity

AU - Mándi, Y.

AU - Farkas, G.

AU - Koltai, M.

AU - Beladi, I.

AU - Mencia-Huerta, J. M.

AU - Braquet,

PY - 1989

Y1 - 1989

N2 - The influence of the platelet-activating factor (PAF) antagonist, BN 52021, on human natural killer (NK) cell cytotoxicity against K 562 target cells was determined. Cytotoxicity was measured by a short-term (4 hr) 51Cr-release assay. The cytotoxicity was significantly reduced in the presence of PAF antagonist at concentrations from 30 to 120 μM. This reduction of killing was not due to the impairment of binding of effector cells to target cells. Pretreatment of K 562 target cells with the PAF antagonist led to a greater inhibition of NK cell cytotoxicity compared with that observed when the effector cells were preincubated with BN 52021. Thus, the inhibition of cytotoxicity appears to be due to an effect of BN 52021 on target cells rather than on lymphocytes. Furthermore, the increase in NK activity induced by interferon was less pronounced when BN 52021 was added in the incubation medium. The natural cytotoxicity of platelet-depleted or large granular lymphocyte-enriched effector cell populations was inhibited by the PAF antagonist in a similar manner. The effect of BN 52021 appears to be related to its specific PAF antagonistic activity since a similar action on NK cells was noted with two other structurally unrelated PAF antagonists, BN 52111 and WEB 2086. In contrast, Ginkgolide J (BN 52024), which is structurally related to BN 52021 but lacks PAF antagonistic activity, was ineffective in inhibiting NK cell cytotoxicity. Finally, synthetic PAF induces a dose-dependent cytotoxic action on K 562 cells and this effect of the autacoid is inhibited by BN 52021. These observations provide indirect evidence that PAF could play a role in the mechanism(s) of NK cytotoxicity.

AB - The influence of the platelet-activating factor (PAF) antagonist, BN 52021, on human natural killer (NK) cell cytotoxicity against K 562 target cells was determined. Cytotoxicity was measured by a short-term (4 hr) 51Cr-release assay. The cytotoxicity was significantly reduced in the presence of PAF antagonist at concentrations from 30 to 120 μM. This reduction of killing was not due to the impairment of binding of effector cells to target cells. Pretreatment of K 562 target cells with the PAF antagonist led to a greater inhibition of NK cell cytotoxicity compared with that observed when the effector cells were preincubated with BN 52021. Thus, the inhibition of cytotoxicity appears to be due to an effect of BN 52021 on target cells rather than on lymphocytes. Furthermore, the increase in NK activity induced by interferon was less pronounced when BN 52021 was added in the incubation medium. The natural cytotoxicity of platelet-depleted or large granular lymphocyte-enriched effector cell populations was inhibited by the PAF antagonist in a similar manner. The effect of BN 52021 appears to be related to its specific PAF antagonistic activity since a similar action on NK cells was noted with two other structurally unrelated PAF antagonists, BN 52111 and WEB 2086. In contrast, Ginkgolide J (BN 52024), which is structurally related to BN 52021 but lacks PAF antagonistic activity, was ineffective in inhibiting NK cell cytotoxicity. Finally, synthetic PAF induces a dose-dependent cytotoxic action on K 562 cells and this effect of the autacoid is inhibited by BN 52021. These observations provide indirect evidence that PAF could play a role in the mechanism(s) of NK cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0024380081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024380081&partnerID=8YFLogxK

M3 - Article

C2 - 2759659

AN - SCOPUS:0024380081

VL - 67

SP - 370

EP - 374

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 3

ER -